biostudies-literatureUnknown57(12)Sebastien BPlerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34⁺ (CD34⁺) cells in the peripheral blood (PB) approximately 10 h after its administration. We developed a model that could predict the CD34⁺ harvest volume on the first day of apheresis (AP-CD34⁺) based on PB-CD34⁺ counts immediately prior to commencing apheresis in pediatric population. In all, data from 45 pediatric patients from the MOZAIC study who received either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF plus plerixafor were included. The modeling of the data exhibited a strong and highly predictive linear relationship between the counts of PB-CD34⁺ cells on the first day of apheresis and AP-CD34⁺ cells collected on the same day. It is predicted that there are approximately 13 new collected CD34⁺ cells for 100 new circulating CD34⁺ cells before apheresis. Our predictive algorithm can be used to quantify the minimal count of PB-CD34⁺ cells that enables to collect at least 2 × 10⁶ or 5 × 10⁶ AP-CD34⁺ cells/kg with sufficient assurance (probability = 0.90) and can guide the use of plerixafor in patients at higher perceived risk for mobilization failure. Trial registration of MOZAIC study: ClinicalTrials.gov, NCT01288573; EudraCT, 2010-019340-40.Bone marrow transplantation1827-1832https://www.ebi.ac.uk/biostudies/studies/S-EPMC9715428biostudies-literatureDevelopment and validation of a predictive model to guide the use of plerixafor in pediatric population.PMC9715428Castan RSebastien BMagnin CCheverton PAouni JfalseDevelopment and validation of a predictive model to guide the use of plerixafor in pediatric population.Plerixafor, a CXCR4 receptor antagonist, reduces the binding and chemotaxis of hematopoietic stem cells to the bone marrow stroma, resulting in predictable peak of cluster of differentiation 34⁺ (CD34⁺) cells in the peripheral blood (PB) approximately 10 h after its administration. We developed a model that could predict the CD34⁺ harvest volume on the first day of apheresis (AP-CD34⁺) based on PB-CD34⁺ counts immediately prior to commencing apheresis in pediatric population. In all, data from 45 pediatric patients from the MOZAIC study who received either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF plus plerixafor were included. The modeling of the data exhibited a strong and highly predictive linear relationship between the counts of PB-CD34⁺ cells on the first day of apheresis and AP-CD34⁺ cells collected on the same day. It is predicted that there are approximately 13 new collected CD34⁺ cells for 100 new circulating CD34⁺ cells before apheresis. Our predictive algorithm can be used to quantify the minimal count of PB-CD34⁺ cells that enables to collect at least 2 × 10⁶ or 5 × 10⁶ AP-CD34⁺ cells/kg with sufficient assurance (probability = 0.90) and can guide the use of plerixafor in patients at higher perceived risk for mobilization failure. Trial registration of MOZAIC study: ClinicalTrials.gov, NCT01288573; EudraCT, 2010-019340-40.2022-01-01T00:00:00Z2022 Dec2026-06-21T03:15:00.654Z2025-04-19T22:50:25.922ZS-EPMC97154283616342710.1038/s41409-022-01831-2